

CORRECTION

Open Access

The B-VITAGE trial: A randomized trial of homocysteine lowering treatment of depression in later life

Andrew H Ford^{1,2,3}, Leon Flicker^{1,4,5}, Kieran McCaul¹, Frank van Bockxmeer^{6,7}, Sarah Hegarty^{1,2}, Varsha Hirani^{1,2}, Stephen Fenner³ and Osvaldo P Almeida^{1,2,3*}

Correction

Following the publication of our article [1], we noticed an error regarding the dosage of vitamin B12. In the manuscript, we reported that the daily dosage of vitamin B12 would be 0.4 mg, when in fact the dosage of vitamin B12 used in the B-VITAGE trial is 0.5 mg per day.

In the abstract:

The B-VITAGE trial is a 12-month randomized, double-blind, placebo-controlled trial of daily citalopram (20 to 40 mg) plus B₁₂(0.4 mg), B₆ (25 mg) and folic acid (2 mg) or citalopram (20 to 40 mg) plus placebo for the treatment of depression in later life.

Should read

The B-VITAGE trial is a 12-month randomized, double-blind, placebo-controlled trial of daily citalopram (20 to 40 mg) plus B₁₂(0.5 mg), B₆ (25 mg) and folic acid (2 mg) or citalopram (20 to 40 mg) plus placebo for the treatment of depression in later life.

In the "Intervention and Blinding" section:

Eligible participants will be randomly allocated to treatment with citalopram plus 400 µg vitamin B₁₂, 2 mg folic acid and 25 mg B₆ or citalopram plus placebo.

Should read

Eligible participants will be randomly allocated to treatment with citalopram plus 500 µg vitamin B₁₂, 2 mg folic acid and 25 mg B₆ or citalopram plus placebo.

Author details

¹Western Australian Centre for Health & Ageing, Centre for Medical Research, University of Western Australia, Perth, Australia. ²School of Psychiatry & Clinical Neurosciences, University of Western Australia, Perth, Australia.

³Department of Psychiatry, Royal Perth Hospital, Perth, Australia. ⁴School of Medicine & Pharmacology, University of Western Australia, Perth, Australia.

⁵Department of Geriatric Medicine, Royal Perth Hospital, Perth, Australia.

* Correspondence: osvaldo.almeida@uwa.edu.au

¹Western Australian Centre for Health & Ageing, Centre for Medical Research, University of Western Australia, Perth, Australia

Full list of author information is available at the end of the article

⁶School of Pathology & Laboratory Medicine, University of Western Australia, Perth, Australia. ⁷Department of Biochemistry, Royal Perth Hospital, Perth, Australia.

Received: 13 July 2011 Accepted: 16 August 2011

Published: 16 August 2011

Reference

1. Ford AH, Flicker L, McCaul K, van Bockxmeer F, Hegarty S, Hirani V, Fenner S, Almeida OP: The B-VITAGE trial: A randomized trial of homocysteine lowering treatment of depression in later life. *Trials* 2010, **11**:8.

doi:10.1186/1745-6215-12-193

Cite this article as: Ford et al.: The B-VITAGE trial: A randomized trial of homocysteine lowering treatment of depression in later life. *Trials* 2011 **12**:193.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

